The mission of the Bioinformatics Shared Resource (BIC) is to provide Mayo Clinic Cancer Center (MCCC) members access to cutting-edge bioinformatics services and research collaborations through a highly experienced team of bioinformaticians. There are 4 categories of service lines offered by the BIC: 1) preprocessing of `omics' data using a suite of cutting-edge workflows; 2) exhaustive annotation services critical to the first-level interpretation of variants; 3) interpretation services (or tertiary analysis) involving pathway analysis; and 4) data-access services that provide centrally managed avenues to external data sources resources such as TCGA, GEO, and GTEX and to internal datasets (Mayo Clinic Biobank, Mayo Genomic Consortium), and genomics data-management solutions for large genomics projects. The BIC has made significant investments in developing the infrastructure to preprocess and interpret genomics data. With the help of Research IT, the bioinformatics technical team has implemented a comprehensive suite of workflows designed by and for faculty. This infrastructure is kept up to date by reviewing and integrating ?best of breed? open-source applications. When a workflow solution is not readily implementable from open-source applications, the BIC engage faculty in the design of novel methods. In addition to preprocessing workflows, applications have been developed to prioritize and filter variants and to visualize variants in the context of biological pathways, complementing a set of licensed commercial applications. Most importantly, the BIC has positioned itself as a bioinformatics research collaborator with MCCC members. BIC has representation at all 3 MCCC sites: Mayo Clinic in Rochester, MN (MCR); Mayo Clinic in Arizona (MCA); and Mayo Clinic in Florida (MCF). Over the last 5 years, BIC has supported more than 1240 projects for 176 MCCC members. During this period, BIC faculty were listed as key personnel on more than 60 submitted grants. Finally, BIC faculty and technical staff were co-authors of over 347 publications with MCCC members. BIC faculty are engaged in the Women's Cancer, Hematologic Malignancies and Gastrointestinal Cancer Programs and their associated Breast, Ovarian, Lymphoma, Multiple Myeloma, and Pancreatic SPOREs. The BIC has established close partnerships with the Genome Analysis Shared Resource and Biostatistics Shared Resource to provide effective and seamless support to MCCC members. The BIC has also partnered with the institution's Research IT resource to establish and maintain the infrastructure needs to manage genomics data and design optimized workflows.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA015083-47
Application #
10113597
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
1997-04-25
Project End
2024-02-29
Budget Start
2021-03-01
Budget End
2022-02-28
Support Year
47
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Liu, Gang; Mukherjee, Bhramar; Lee, Seunggeun et al. (2018) Robust Tests for Additive Gene-Environment Interaction in Case-Control Studies Using Gene-Environment Independence. Am J Epidemiol 187:366-377
Ong, Jue-Sheng; Hwang, Liang-Dar; Cuellar-Partida, Gabriel et al. (2018) Assessment of moderate coffee consumption and risk of epithelial ovarian cancer: a Mendelian randomization study. Int J Epidemiol 47:450-459
Kumar, Shaji K; Buadi, Francis K; LaPlant, Betsy et al. (2018) Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma. Blood Cancer J 8:70
Schafer, Eric S; Rau, Rachel E; Berg, Stacey et al. (2018) A phase 1 study of eribulin mesylate (E7389), a novel microtubule-targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314). Pediatr Blood Cancer 65:e27066
Kalli, Kimberly R; Block, Matthew S; Kasi, Pashtoon M et al. (2018) Folate Receptor Alpha Peptide Vaccine Generates Immunity in Breast and Ovarian Cancer Patients. Clin Cancer Res 24:3014-3025
Norris, Robin E; Fox, Elizabeth; Reid, Joel M et al. (2018) Phase 1 trial of ontuxizumab (MORAb-004) in children with relapsed or refractory solid tumors: A report from the Children's Oncology Group Phase 1 Pilot Consortium (ADVL1213). Pediatr Blood Cancer 65:e26944
Wang, Sophia S; Carrington, Mary; Berndt, Sonja I et al. (2018) HLA Class I and II Diversity Contributes to the Etiologic Heterogeneity of Non-Hodgkin Lymphoma Subtypes. Cancer Res 78:4086-4096
Block, Matthew S; Vierkant, Robert A; Rambau, Peter F et al. (2018) MyD88 and TLR4 Expression in Epithelial Ovarian Cancer. Mayo Clin Proc 93:307-320
Sharma, Ayush; Oishi, Naoki; Boddicker, Rebecca L et al. (2018) Recurrent STAT3-JAK2 fusions in indolent T-cell lymphoproliferative disorder of the gastrointestinal tract. Blood 131:2262-2266
Langlais, Blake T; Geyer, Holly; Scherber, Robyn et al. (2018) Quality of life and symptom burden among myeloproliferative neoplasm patients: do symptoms impact quality of life? Leuk Lymphoma :1-7

Showing the most recent 10 out of 1129 publications